[Experimental treatment with fumaric acid monoethylester in psoriasis vulgaris].
D000284:Administration, Oral; D000328:Adult; D001806:Blood Urea Nitrogen; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D003875:Drug Eruptions / Q000209:etiology; D004952:Esters; D005334:Fever / Q000139:chemically induced; D005650:Fumarates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006029:Glycosuria / Q000139:chemically induced; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D007962:Leukocytes; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011565:Psoriasis / Q000188:drug therapy*; D014527:Uric Acid / Q000097:blood; D014558:Urobilinogen / Q000652:urine; D014839:Vomiting / Q000139:chemically induced
D004952:Esters; D005650:Fumarates; D014558:Urobilinogen; D014527:Uric Acid; D003404:Creatinine
Behandlungsversuch mit Fumarsäuremonoäthylester bei Psoriasis vulgaris.